- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Merck & Co. received FDA approval for Doravirine and is conducting clinical studies in Kenya, South Africa, and Uganda, supported by the Gates Foundation.
1 report, 1 independent
Updated Jul 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck & Co. received FDA approval for Doravirine and is conducting clinical studies in Kenya, South Africa, and Uganda, supported by the Gates Foundation.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Merck KGaA
German multinational science and technology company
Related events
Coverage
Newest first; wire copies grouped- ZacksMerck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for